Characterisation of systemic dissemination of nonreplicating adenoviral vectors from tumours in local gene delivery

被引:27
作者
Wang, Y
Yang, Z
Liu, S
Kon, T
Krol, A
Li, CY
Yuan, F
机构
[1] Duke Univ, Dept Biomed Engn, Durham, NC 27708 USA
[2] Duke Univ, Med Ctr, Dept Radiat Oncol, Durham, NC 27710 USA
关键词
gene delivery; virus dissemination; intratumoral infusion;
D O I
10.1038/sj.bjc.6602494
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Systemic virus dissemination is a potential problem during local gene delivery in solid tumours. However, the kinetics and pathways of the dissemination have not been well characterised during the first 24 h after the infusion is started. To this end, we infused adenoviral vectors for luciferase or enhanced green fluorescence protein into three different tumour models in mice. During and/or after the infusion, we determined the amount of adenoviruses in the tumour, blood, and liver, and examined the transgene expression in the liver, lung, blood, and tumour. In addition, we intravenously injected tumour cells expressing luciferase and examined the biodistribution of these cells in the body. We observed transgene expression in the liver and tumour at 24 h after the infusion, but could not detect transgene expression in the blood and lung. The peak concentration of viral vectors in the plasma occurred during the intratumoral infusion. At 10 min after the infusion, few viral vectors remained in the blood and the ratio of copy numbers of adenoviruses between liver and tumour was 42 in 80% and >= 10 in 40% of the mice. Most tumour cells injected intravenously accumulated in the lung within the first 24 h. Taken together, these data indicated that systemic virus dissemination occurred mainly during the first 10 min after the intratumoral infusion was started, and that the dissemination was due to infusion-induced convective transport of viral vectors into leaky tumour microvessels.
引用
收藏
页码:1414 / 1420
页数:7
相关论文
共 56 条
  • [1] Use of transcriptional regulatory sequences of telomerase (hTER and hTERT) for selective killing of cancer cells
    Abdul-Ghani, R
    Ohana, P
    Matouk, I
    Ayesh, S
    Ayesh, B
    Laster, M
    Bibi, O
    Giladi, H
    Molnar-Kimber, K
    Sughayer, MA
    de Groot, N
    Hochberg, A
    [J]. MOLECULAR THERAPY, 2000, 2 (06) : 539 - 544
  • [2] Adachi Y, 2001, CANCER RES, V61, P7882
  • [3] Blood clearance rates of adenovirus type 5 in mice
    Alemany, R
    Suzuki, K
    Curiel, DT
    [J]. JOURNAL OF GENERAL VIROLOGY, 2000, 81 : 2605 - 2609
  • [4] Replicative adenoviruses for cancer therapy
    Alemany, R
    Balagué, C
    Curiel, DT
    [J]. NATURE BIOTECHNOLOGY, 2000, 18 (07) : 723 - 727
  • [5] A phase I study of recombinant adenovirus vector-mediated intraperitoneal delivery of herpes simplex virus thymidine kinase (HSV-TK) gene and intravenous ganciclovir for previously treated ovarian and extraovarian cancer patients
    Alvarez, RD
    Curiel, DT
    [J]. HUMAN GENE THERAPY, 1997, 8 (05) : 597 - 613
  • [6] Anderson WF, 1998, NATURE, V392, P25
  • [7] Evolution of cell recognition by viruses
    Baranowski, E
    Ruiz-Jarabo, CM
    Domingo, E
    [J]. SCIENCE, 2001, 292 (5519) : 1102 - 1105
  • [8] Blackburn RV, 1998, CANCER RES, V58, P1358
  • [9] Immune responses to replication-defective HSV-1 type vectors within the CNS: implications for gene therapy
    Bowers, WJ
    Olschowka, JA
    Federoff, HJ
    [J]. GENE THERAPY, 2003, 10 (11) : 941 - 945
  • [10] Pre-existing immunity to adenovirus does not prevent tumor regression following intratumoral administration of a vector expressing IL-12 but inhibits virus dissemination
    Bramson, JL
    Hitt, M
    Gauldie, J
    Graham, FL
    [J]. GENE THERAPY, 1997, 4 (10) : 1069 - 1076